Evidence map›Paper›PMID 29894201›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2018

In situ type I oligomeric collagen macroencapsulation promotes islet longevity and function in vitro and in vivo.

Clarissa Hernandez Stephens, Kara S Orr, Anthony J Acton, Sarah A Tersey, Raghavendra G Mirmira, Robert V Considine, Sherry L Voytik-Harbin

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Clarissa Hernandez StephensWeldon School of Biomedical Engineering, Purdue University , West Lafayette, Indiana.
Kara S OrrCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine , Indianapolis, Indiana.
Anthony J ActonCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine , Indianapolis, Indiana.
Sarah A TerseyCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine , Indianapolis, Indiana.
Raghavendra G MirmiraCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine , Indianapolis, Indiana.
Robert V ConsidineCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine , Indianapolis, Indiana.
Sherry L Voytik-HarbinWeldon School of Biomedical Engineering, Purdue University , West Lafayette, Indiana.
Indiana University – Purdue University Indianapolis · USIndiana University School of MedicinePurdue University West Lafayette · US

Funding

Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2015 to 2026
$17.4M
Transcriptional Mechanisms Governing Beta Cell DifferentiationR01DK060581 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Raghavendra G Mirmira · 2002 to 2026
$8.5M
Interdisciplinary Bioengineering Training in Diabetes ResearchT32DK101001 · NIDDK · PURDUE UNIVERSITY · PI EVANS-MOLINA, CARMELLA, VOYTIK-HARBIN, SHERRY L · 2013 to 2022
$1.6M
Long-term non-enzymatic glucose sensor for an artificial pancreasR44DK101000 · NIDDK · PROFUSA, INC. · PI WISNIEWSKI, NATALIE ANN · 2016 to 2017
$1.5M
Late stage development and preparation of a long-term non-enzymatic continuous glucose sensor for clinical trialsSB1DK101000 · NIDDK · PROFUSA, INC. · PI GAMSEY, SOYA, REBRIN, KERSTIN · 2018 to 2019
$962k
Long-Term Non-Enzymatic Glucose Sensors for an Artificial PancreasR43DK101000 · NIDDK · PROFUSA, INC. · PI WISNIEWSKI, NATALIE ANN · 2013 to 2014
$252k
NIDDK NIH HHS P30 DK097512NIDDK NIH HHS R01 DK060581NIDDK NIH HHS R43 DK101000NIDDK NIH HHS R44 DK101000NIDDK NIH HHS SB1 DK101000NIDDK NIH HHS T32 DK101001
6 · The paper itself

Abstract

Widespread use of pancreatic islet transplantation for treatment of type 1 diabetes (T1D) is currently limited by requirements for long-term immunosuppression, limited donor supply, and poor long-term engraftment and function. Upon isolation from their native microenvironment, islets undergo rapid apoptosis, which is further exacerbated by poor oxygen and nutrient supply following infusion into the portal vein. Identifying alternative strategies to restore critical microenvironmental cues, while maximizing islet health and function, is needed to advance this cellular therapy. We hypothesized that biophysical properties provided through type I oligomeric collagen macroencapsulation are important considerations when designing strategies to improve islet survival, phenotype, and function. Mouse islets were encapsulated at various Oligomer concentrations (0.5 -3.0 mg/ml) or suspended in media and cultured for 14 days, after which viability, protein expression, and function were assessed. Oligomer-encapsulated islets showed a density-dependent improvement in in vitro viability, cytoarchitecture, and insulin secretion, with 3 mg/ml yielding values comparable to freshly isolated islets. For transplantation into streptozotocin-induced diabetic mice, 500 islets were mixed in Oligomer and injected subcutaneously, where rapid in situ macroencapsulation occurred, or injected with saline. Mice treated with Oligomer-encapsulated islets exhibited rapid (within 24 h) diabetes reversal and maintenance of normoglycemia for 14 (immunocompromised), 90 (syngeneic), and 40 days (allogeneic). Histological analysis showed Oligomer-islet engraftment with maintenance of islet cytoarchitecture, revascularization, and no foreign body response. Oligomer-islet macroencapsulation may provide a useful strategy for prolonging the health and function of cultured islets and has potential as a subcutaneous injectable islet transplantation strategy for treatment of T1D.

Indexed as

Graft SurvivalInsulin SecretionTissue SurvivalAnimalsCollagen Type ICulture TechniquesDermisDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Fibrillar CollagensIn Vitro TechniquesIslets of LangerhansIslets of Langerhans TransplantationMiceMicroscopy, ConfocalPolymerizationCollagen Type IFibrillar Collagensislet encapsulationsubcutaneoustype 1 diabetestype I collagen oligomers

Identifiers

PMID29894201
PMCPMC6230705
OpenAlexW2807915252

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.